 | • レポートコード：MRC2-11QY01517 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は高リン血症薬のグローバル市場について調査・分析したレポートです。種類別（アルミニウムリン吸着剤、鉄リン吸着剤、リン酸マグネシウム結合剤、カルシウムリン吸着剤）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別高リン血症薬の競争状況、市場シェア ・世界の高リン血症薬市場：種類別市場規模 2015年-2020年（アルミニウムリン吸着剤、鉄リン吸着剤、リン酸マグネシウム結合剤、カルシウムリン吸着剤） ・世界の高リン血症薬市場：種類別市場規模予測 2021年-2026年（アルミニウムリン吸着剤、鉄リン吸着剤、リン酸マグネシウム結合剤、カルシウムリン吸着剤） ・世界の高リン血症薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の高リン血症薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の高リン血症薬市場分析：米国、カナダ ・ヨーロッパの高リン血症薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの高リン血症薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の高リン血症薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの高リン血症薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Keryx Biopharmaceuticals、Sanofi、Takeda、Vifor Pharma、Amgen、Bayer ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
hosphorus is an important element for normal physiologic functions such as bone construction, nerve function, and muscle contraction. About 85% of phosphorus is stored in the bones and different tissues in the body. The excess phosphorus is eliminated from the body by the urinary system. The normal phosphate level in the blood is 3-4 mg/dL. Electrolytic disturbance resulting in high levels of phosphate in the blood causes hyperphosphatemia. Individuals with chronic kidney diseases have a decreased glomerular filtration rate and increased serum phosphate levels. The high phosphate levels in the serum lower calcium levels because of phosphate precipitation by calcium ions, leading to calcification of vascular tissues and heart diseases. Aluminum-, calcium-, magnesium-, and iron-based and aluminum-free, calcium-free phosphate binders are used to treat the condition.
Major factors driving the market include rise in prevalence of chronic diseases, high unmet medical needs, increase in the number of people undergoing dialysis, large geriatric population, and surge in public awareness worldwide. Diabetes and hypertension are the main causes of renal failure, which leads to hyperphosphatemia. However, stringent regulations by regulatory bodies such as the Food and Drug Administration (FDA), non-adherence to treatment regimens, and rise in side effects of hyperphosphatemia drugs are likely to inhibit the market. According to FDA use of hyperphosphatemia drugs for the treatment of high or low phosphorus levels in the human body is neither safe nor effective. High growth potential in untapped economies, such as India, China, South Africa, and Brazil, is expected to create lucrative opportunities for key players. Rise in geriatric population and increase in cases of osteoporosis in Asia Pacific is anticipated to drive the market. Osteoporosis is often undertreated and underdiagnosed, which is driving the hyperphosphatemia drugs market in Asia Pacific. The available calcium, lanthanum, sevelamer, and iron-based drugs for treating hyperphosphatemia are associated with certain side effects. The long-term use of calcium-based drugs such as calcium carbonate and calcium acetate can cause vascular calcification.
Market Analysis and Insights: Global Hyperphosphatemia Drugs Market
The global Hyperphosphatemia Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hyperphosphatemia Drugs Scope and Market Size
Hyperphosphatemia Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hyperphosphatemia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Hyperphosphatemia Drugs market is segmented into
Aluminum Phosphate Binder
Iron Phosphate Binder
Magnesium Phosphate Binder
Calcium Phosphate Binder
Segment by Application, the Hyperphosphatemia Drugs market is segmented into
Hospitals
Clinics
Others
Regional and Country-level Analysis
The Hyperphosphatemia Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Hyperphosphatemia Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Hyperphosphatemia Drugs Market Share Analysis
Hyperphosphatemia Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hyperphosphatemia Drugs business, the date to enter into the Hyperphosphatemia Drugs market, Hyperphosphatemia Drugs product introduction, recent developments, etc.
The major vendors covered:
Keryx Biopharmaceuticals
Sanofi
Takeda
Vifor Pharma
Amgen
Bayer
…
1 Study Coverage
1.1 Hyperphosphatemia Drugs Product Introduction
1.2 Market Segments
1.3 Key Hyperphosphatemia Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Hyperphosphatemia Drugs Market Size Growth Rate by Type
1.4.2 Aluminum Phosphate Binder
1.4.3 Iron Phosphate Binder
1.4.4 Magnesium Phosphate Binder
1.4.5 Calcium Phosphate Binder
1.5 Market by Application
1.5.1 Global Hyperphosphatemia Drugs Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Hyperphosphatemia Drugs Market Size, Estimates and Forecasts
2.1.1 Global Hyperphosphatemia Drugs Revenue 2015-2026
2.1.2 Global Hyperphosphatemia Drugs Sales 2015-2026
2.2 Global Hyperphosphatemia Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Hyperphosphatemia Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Hyperphosphatemia Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Hyperphosphatemia Drugs Competitor Landscape by Players
3.1 Hyperphosphatemia Drugs Sales by Manufacturers
3.1.1 Hyperphosphatemia Drugs Sales by Manufacturers (2015-2020)
3.1.2 Hyperphosphatemia Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Hyperphosphatemia Drugs Revenue by Manufacturers
3.2.1 Hyperphosphatemia Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Hyperphosphatemia Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Hyperphosphatemia Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Hyperphosphatemia Drugs Revenue in 2019
3.2.5 Global Hyperphosphatemia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Hyperphosphatemia Drugs Price by Manufacturers
3.4 Hyperphosphatemia Drugs Manufacturing Base Distribution, Product Types
3.4.1 Hyperphosphatemia Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Hyperphosphatemia Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Hyperphosphatemia Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hyperphosphatemia Drugs Market Size by Type (2015-2020)
4.1.1 Global Hyperphosphatemia Drugs Sales by Type (2015-2020)
4.1.2 Global Hyperphosphatemia Drugs Revenue by Type (2015-2020)
4.1.3 Hyperphosphatemia Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Hyperphosphatemia Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Hyperphosphatemia Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Hyperphosphatemia Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Hyperphosphatemia Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Hyperphosphatemia Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Hyperphosphatemia Drugs Market Size by Application (2015-2020)
5.1.1 Global Hyperphosphatemia Drugs Sales by Application (2015-2020)
5.1.2 Global Hyperphosphatemia Drugs Revenue by Application (2015-2020)
5.1.3 Hyperphosphatemia Drugs Price by Application (2015-2020)
5.2 Hyperphosphatemia Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Hyperphosphatemia Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Hyperphosphatemia Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Hyperphosphatemia Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Hyperphosphatemia Drugs by Country
6.1.1 North America Hyperphosphatemia Drugs Sales by Country
6.1.2 North America Hyperphosphatemia Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Hyperphosphatemia Drugs Market Facts & Figures by Type
6.3 North America Hyperphosphatemia Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Hyperphosphatemia Drugs by Country
7.1.1 Europe Hyperphosphatemia Drugs Sales by Country
7.1.2 Europe Hyperphosphatemia Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Hyperphosphatemia Drugs Market Facts & Figures by Type
7.3 Europe Hyperphosphatemia Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Hyperphosphatemia Drugs by Region
8.1.1 Asia Pacific Hyperphosphatemia Drugs Sales by Region
8.1.2 Asia Pacific Hyperphosphatemia Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Hyperphosphatemia Drugs Market Facts & Figures by Type
8.3 Asia Pacific Hyperphosphatemia Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Hyperphosphatemia Drugs by Country
9.1.1 Latin America Hyperphosphatemia Drugs Sales by Country
9.1.2 Latin America Hyperphosphatemia Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Hyperphosphatemia Drugs Market Facts & Figures by Type
9.3 Central & South America Hyperphosphatemia Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Hyperphosphatemia Drugs by Country
10.1.1 Middle East and Africa Hyperphosphatemia Drugs Sales by Country
10.1.2 Middle East and Africa Hyperphosphatemia Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Hyperphosphatemia Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Hyperphosphatemia Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Keryx Biopharmaceuticals
11.1.1 Keryx Biopharmaceuticals Corporation Information
11.1.2 Keryx Biopharmaceuticals Description and Business Overview
11.1.3 Keryx Biopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Keryx Biopharmaceuticals Hyperphosphatemia Drugs Products Offered
11.1.5 Keryx Biopharmaceuticals Related Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Description and Business Overview
11.2.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Sanofi Hyperphosphatemia Drugs Products Offered
11.2.5 Sanofi Related Developments
11.3 Takeda
11.3.1 Takeda Corporation Information
11.3.2 Takeda Description and Business Overview
11.3.3 Takeda Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Takeda Hyperphosphatemia Drugs Products Offered
11.3.5 Takeda Related Developments
11.4 Vifor Pharma
11.4.1 Vifor Pharma Corporation Information
11.4.2 Vifor Pharma Description and Business Overview
11.4.3 Vifor Pharma Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Vifor Pharma Hyperphosphatemia Drugs Products Offered
11.4.5 Vifor Pharma Related Developments
11.5 Amgen
11.5.1 Amgen Corporation Information
11.5.2 Amgen Description and Business Overview
11.5.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Amgen Hyperphosphatemia Drugs Products Offered
11.5.5 Amgen Related Developments
11.6 Bayer
11.6.1 Bayer Corporation Information
11.6.2 Bayer Description and Business Overview
11.6.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Bayer Hyperphosphatemia Drugs Products Offered
11.6.5 Bayer Related Developments
11.1 Keryx Biopharmaceuticals
11.1.1 Keryx Biopharmaceuticals Corporation Information
11.1.2 Keryx Biopharmaceuticals Description and Business Overview
11.1.3 Keryx Biopharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Keryx Biopharmaceuticals Hyperphosphatemia Drugs Products Offered
11.1.5 Keryx Biopharmaceuticals Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Hyperphosphatemia Drugs Market Estimates and Projections by Region
12.1.1 Global Hyperphosphatemia Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Hyperphosphatemia Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Hyperphosphatemia Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Hyperphosphatemia Drugs Sales Forecast (2021-2026)
12.2.2 North America: Hyperphosphatemia Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Hyperphosphatemia Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Hyperphosphatemia Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Hyperphosphatemia Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Hyperphosphatemia Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Hyperphosphatemia Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Hyperphosphatemia Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Hyperphosphatemia Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Hyperphosphatemia Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Hyperphosphatemia Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Hyperphosphatemia Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Hyperphosphatemia Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Hyperphosphatemia Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Hyperphosphatemia Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Hyperphosphatemia Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Hyperphosphatemia Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Hyperphosphatemia Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Hyperphosphatemia Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Hyperphosphatemia Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Hyperphosphatemia Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Hyperphosphatemia Drugs Market Segments
Table 2. Ranking of Global Top Hyperphosphatemia Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Hyperphosphatemia Drugs Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Aluminum Phosphate Binder
Table 5. Major Manufacturers of Iron Phosphate Binder
Table 6. Major Manufacturers of Magnesium Phosphate Binder
Table 7. Major Manufacturers of Calcium Phosphate Binder
Table 8. Global Hyperphosphatemia Drugs Market Size Growth Rate by Application 2020-2026 (K MT)
Table 9. Global Hyperphosphatemia Drugs Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 10. Global Hyperphosphatemia Drugs Sales by Regions 2015-2020 (K MT)
Table 11. Global Hyperphosphatemia Drugs Sales Market Share by Regions (2015-2020)
Table 12. Global Hyperphosphatemia Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global Hyperphosphatemia Drugs Sales by Manufacturers (2015-2020) (K MT)
Table 14. Global Hyperphosphatemia Drugs Sales Share by Manufacturers (2015-2020)
Table 15. Global Hyperphosphatemia Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global Hyperphosphatemia Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hyperphosphatemia Drugs as of 2019)
Table 17. Hyperphosphatemia Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. Hyperphosphatemia Drugs Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers Hyperphosphatemia Drugs Price (2015-2020) (USD/MT)
Table 20. Hyperphosphatemia Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers Hyperphosphatemia Drugs Product Type
Table 22. Date of International Manufacturers Enter into Hyperphosphatemia Drugs Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global Hyperphosphatemia Drugs Sales by Type (2015-2020) (K MT)
Table 25. Global Hyperphosphatemia Drugs Sales Share by Type (2015-2020)
Table 26. Global Hyperphosphatemia Drugs Revenue by Type (2015-2020) (US$ Million)
Table 27. Global Hyperphosphatemia Drugs Revenue Share by Type (2015-2020)
Table 28. Hyperphosphatemia Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 29. Global Hyperphosphatemia Drugs Sales by Application (2015-2020) (K MT)
Table 30. Global Hyperphosphatemia Drugs Sales Share by Application (2015-2020)
Table 31. North America Hyperphosphatemia Drugs Sales by Country (2015-2020) (K MT)
Table 32. North America Hyperphosphatemia Drugs Sales Market Share by Country (2015-2020)
Table 33. North America Hyperphosphatemia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 34. North America Hyperphosphatemia Drugs Revenue Market Share by Country (2015-2020)
Table 35. North America Hyperphosphatemia Drugs Sales by Type (2015-2020) (K MT)
Table 36. North America Hyperphosphatemia Drugs Sales Market Share by Type (2015-2020)
Table 37. North America Hyperphosphatemia Drugs Sales by Application (2015-2020) (K MT)
Table 38. North America Hyperphosphatemia Drugs Sales Market Share by Application (2015-2020)
Table 39. Europe Hyperphosphatemia Drugs Sales by Country (2015-2020) (K MT)
Table 40. Europe Hyperphosphatemia Drugs Sales Market Share by Country (2015-2020)
Table 41. Europe Hyperphosphatemia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe Hyperphosphatemia Drugs Revenue Market Share by Country (2015-2020)
Table 43. Europe Hyperphosphatemia Drugs Sales by Type (2015-2020) (K MT)
Table 44. Europe Hyperphosphatemia Drugs Sales Market Share by Type (2015-2020)
Table 45. Europe Hyperphosphatemia Drugs Sales by Application (2015-2020) (K MT)
Table 46. Europe Hyperphosphatemia Drugs Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific Hyperphosphatemia Drugs Sales by Region (2015-2020) (K MT)
Table 48. Asia Pacific Hyperphosphatemia Drugs Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific Hyperphosphatemia Drugs Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific Hyperphosphatemia Drugs Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific Hyperphosphatemia Drugs Sales by Type (2015-2020) (K MT)
Table 52. Asia Pacific Hyperphosphatemia Drugs Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific Hyperphosphatemia Drugs Sales by Application (2015-2020) (K MT)
Table 54. Asia Pacific Hyperphosphatemia Drugs Sales Market Share by Application (2015-2020)
Table 55. Latin America Hyperphosphatemia Drugs Sales by Country (2015-2020) (K MT)
Table 56. Latin America Hyperphosphatemia Drugs Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa Hyperphosphatemia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America Hyperphosphatemia Drugs Revenue Market Share by Country (2015-2020)
Table 59. Latin America Hyperphosphatemia Drugs Sales by Type (2015-2020) (K MT)
Table 60. Latin America Hyperphosphatemia Drugs Sales Market Share by Type (2015-2020)
Table 61. Latin America Hyperphosphatemia Drugs Sales by Application (2015-2020) (K MT)
Table 62. Latin America Hyperphosphatemia Drugs Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa Hyperphosphatemia Drugs Sales by Country (2015-2020) (K MT)
Table 64. Middle East and Africa Hyperphosphatemia Drugs Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa Hyperphosphatemia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa Hyperphosphatemia Drugs Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa Hyperphosphatemia Drugs Sales by Type (2015-2020) (K MT)
Table 68. Middle East and Africa Hyperphosphatemia Drugs Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa Hyperphosphatemia Drugs Sales by Application (2015-2020) (K MT)
Table 70. Middle East and Africa Hyperphosphatemia Drugs Sales Market Share by Application (2015-2020)
Table 71. Keryx Biopharmaceuticals Corporation Information
Table 72. Keryx Biopharmaceuticals Description and Major Businesses
Table 73. Keryx Biopharmaceuticals Hyperphosphatemia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 74. Keryx Biopharmaceuticals Product
Table 75. Keryx Biopharmaceuticals Recent Development
Table 76. Sanofi Corporation Information
Table 77. Sanofi Description and Major Businesses
Table 78. Sanofi Hyperphosphatemia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 79. Sanofi Product
Table 80. Sanofi Recent Development
Table 81. Takeda Corporation Information
Table 82. Takeda Description and Major Businesses
Table 83. Takeda Hyperphosphatemia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 84. Takeda Product
Table 85. Takeda Recent Development
Table 86. Vifor Pharma Corporation Information
Table 87. Vifor Pharma Description and Major Businesses
Table 88. Vifor Pharma Hyperphosphatemia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 89. Vifor Pharma Product
Table 90. Vifor Pharma Recent Development
Table 91. Amgen Corporation Information
Table 92. Amgen Description and Major Businesses
Table 93. Amgen Hyperphosphatemia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 94. Amgen Product
Table 95. Amgen Recent Development
Table 96. Bayer Corporation Information
Table 97. Bayer Description and Major Businesses
Table 98. Bayer Hyperphosphatemia Drugs Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 99. Bayer Product
Table 100. Bayer Recent Development
Table 101. Global Hyperphosphatemia Drugs Sales Forecast by Regions (2021-2026) (K MT)
Table 102. Global Hyperphosphatemia Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 103. Global Hyperphosphatemia Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 104. Global Hyperphosphatemia Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 105. North America: Hyperphosphatemia Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 106. North America: Hyperphosphatemia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 107. Europe: Hyperphosphatemia Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 108. Europe: Hyperphosphatemia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 109. Asia Pacific: Hyperphosphatemia Drugs Sales Forecast by Region (2021-2026) (K MT)
Table 110. Asia Pacific: Hyperphosphatemia Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 111. Latin America: Hyperphosphatemia Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 112. Latin America: Hyperphosphatemia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 113. Middle East and Africa: Hyperphosphatemia Drugs Sales Forecast by Country (2021-2026) (K MT)
Table 114. Middle East and Africa: Hyperphosphatemia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 115. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 116. Key Challenges
Table 117. Market Risks
Table 118. Main Points Interviewed from Key Hyperphosphatemia Drugs Players
Table 119. Hyperphosphatemia Drugs Customers List
Table 120. Hyperphosphatemia Drugs Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Hyperphosphatemia Drugs Product Picture
Figure 2. Global Hyperphosphatemia Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Aluminum Phosphate Binder Product Picture
Figure 4. Iron Phosphate Binder Product Picture
Figure 5. Magnesium Phosphate Binder Product Picture
Figure 6. Calcium Phosphate Binder Product Picture
Figure 7. Global Hyperphosphatemia Drugs Sales Market Share by Application in 2020 & 2026
Figure 8. Hospitals
Figure 9. Clinics
Figure 10. Others
Figure 11. Hyperphosphatemia Drugs Report Years Considered
Figure 12. Global Hyperphosphatemia Drugs Market Size 2015-2026 (US$ Million)
Figure 13. Global Hyperphosphatemia Drugs Sales 2015-2026 (K MT)
Figure 14. Global Hyperphosphatemia Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global Hyperphosphatemia Drugs Sales Market Share by Region (2015-2020)
Figure 16. Global Hyperphosphatemia Drugs Sales Market Share by Region in 2019
Figure 17. Global Hyperphosphatemia Drugs Revenue Market Share by Region (2015-2020)
Figure 18. Global Hyperphosphatemia Drugs Revenue Market Share by Region in 2019
Figure 19. Global Hyperphosphatemia Drugs Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by Hyperphosphatemia Drugs Revenue in 2019
Figure 21. Hyperphosphatemia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global Hyperphosphatemia Drugs Sales Market Share by Type (2015-2020)
Figure 23. Global Hyperphosphatemia Drugs Sales Market Share by Type in 2019
Figure 24. Global Hyperphosphatemia Drugs Revenue Market Share by Type (2015-2020)
Figure 25. Global Hyperphosphatemia Drugs Revenue Market Share by Type in 2019
Figure 26. Global Hyperphosphatemia Drugs Market Share by Price Range (2015-2020)
Figure 27. Global Hyperphosphatemia Drugs Sales Market Share by Application (2015-2020)
Figure 28. Global Hyperphosphatemia Drugs Sales Market Share by Application in 2019
Figure 29. Global Hyperphosphatemia Drugs Revenue Market Share by Application (2015-2020)
Figure 30. Global Hyperphosphatemia Drugs Revenue Market Share by Application in 2019
Figure 31. North America Hyperphosphatemia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 32. North America Hyperphosphatemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America Hyperphosphatemia Drugs Sales Market Share by Country in 2019
Figure 34. North America Hyperphosphatemia Drugs Revenue Market Share by Country in 2019
Figure 35. U.S. Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 36. U.S. Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 38. Canada Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America Hyperphosphatemia Drugs Market Share by Type in 2019
Figure 40. North America Hyperphosphatemia Drugs Market Share by Application in 2019
Figure 41. Europe Hyperphosphatemia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 42. Europe Hyperphosphatemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe Hyperphosphatemia Drugs Sales Market Share by Country in 2019
Figure 44. Europe Hyperphosphatemia Drugs Revenue Market Share by Country in 2019
Figure 45. Germany Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 46. Germany Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 48. France Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 50. U.K. Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 52. Italy Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 54. Russia Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe Hyperphosphatemia Drugs Market Share by Type in 2019
Figure 56. Europe Hyperphosphatemia Drugs Market Share by Application in 2019
Figure 57. Asia Pacific Hyperphosphatemia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 58. Asia Pacific Hyperphosphatemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific Hyperphosphatemia Drugs Sales Market Share by Region in 2019
Figure 60. Asia Pacific Hyperphosphatemia Drugs Revenue Market Share by Region in 2019
Figure 61. China Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 62. China Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 64. Japan Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 66. South Korea Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 68. India Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 70. Australia Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 72. Taiwan Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 74. Indonesia Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 76. Thailand Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 78. Malaysia Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 80. Philippines Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 82. Vietnam Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific Hyperphosphatemia Drugs Market Share by Type in 2019
Figure 84. Asia Pacific Hyperphosphatemia Drugs Market Share by Application in 2019
Figure 85. Latin America Hyperphosphatemia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 86. Latin America Hyperphosphatemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America Hyperphosphatemia Drugs Sales Market Share by Country in 2019
Figure 88. Latin America Hyperphosphatemia Drugs Revenue Market Share by Country in 2019
Figure 89. Mexico Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 90. Mexico Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 92. Brazil Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 94. Argentina Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America Hyperphosphatemia Drugs Market Share by Type in 2019
Figure 96. Latin America Hyperphosphatemia Drugs Market Share by Application in 2019
Figure 97. Middle East and Africa Hyperphosphatemia Drugs Sales Growth Rate 2015-2020 (K MT)
Figure 98. Middle East and Africa Hyperphosphatemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa Hyperphosphatemia Drugs Sales Market Share by Country in 2019
Figure 100. Middle East and Africa Hyperphosphatemia Drugs Revenue Market Share by Country in 2019
Figure 101. Turkey Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 102. Turkey Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 104. Saudi Arabia Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E Hyperphosphatemia Drugs Sales Growth Rate (2015-2020) (K MT)
Figure 106. U.A.E Hyperphosphatemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa Hyperphosphatemia Drugs Market Share by Type in 2019
Figure 108. Middle East and Africa Hyperphosphatemia Drugs Market Share by Application in 2019
Figure 109. North America Hyperphosphatemia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 110. North America Hyperphosphatemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe Hyperphosphatemia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 112. Europe Hyperphosphatemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific Hyperphosphatemia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 114. Asia Pacific Hyperphosphatemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America Hyperphosphatemia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 116. Latin America Hyperphosphatemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa Hyperphosphatemia Drugs Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 118. Middle East and Africa Hyperphosphatemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
バインダークリップの世界市場（～2026年） Market Analysis and Insights: Global Binder Clips Market The global Binder Clips market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Binder Clips Scope and Market Size Binder Clips market is segmented by Type, and by Appli…- マイコトキシン結合剤の世界市場（～2026年） Market Analysis and Insights: Global Mycotoxin Binder Market The global Mycotoxin Binder market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Mycotoxin Binder Scope and Market Size Mycotoxin Binder market is segmented by Ty…
- ポリマーバインダーの世界市場（～2026年） Polymer binder, as a key component in maintaining the structural integrity during the volume change with pre-formed SEI effect. Market Analysis and Insights: Global Polymer Binder Market The global Polymer Binder market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, …
- 飼料用マイコトキシン結合剤の世界市場（～2026年） Market Analysis and Insights: Global Feed Mycotoxin Binder Market The global Feed Mycotoxin Binder market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Feed Mycotoxin Binder Scope and Market Size Feed Mycotoxin Binder marke…
- リン酸二水素カルシウムの世界市場（～2026年） Market Analysis and Insights: Global Calcium Dihydrogen Phosphate Market The global Calcium Dihydrogen Phosphate market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Calcium Dihydrogen Phosphate Scope and Market Size Calciu…